Artemida Pharma Ltd
ARTEMIDA PHARMA LTD
Stevenage Bioscience Catalyst,
Gunnels Wood Road,
Hertfordshire SG1 2FX
ARTEMIDA PHARMA EUROPE LTD
Fitzwilliam Hall, Fitzwilliam Place,
Tel/fax: +44 (0)800 689 4391
- 2018 International Trade
Artemida Pharma Ltd, incorporating Artemida Pharma Europe Ltd, is a well-established drug development consultancy with a specialism in oncology. It offers optimised strategic drug development from product concept to clinical proof of concept for biotech and pharma clients.
Over the past 20 years the team has been involved in the provision of development planning for oncology indications in both solid and haematological tumours. Its involvement commences with mode of action or potential target elucidation and indication seeking to optimise the development pathway and assist companies in moving to proof of concept. Identification of the most appropriate development and regulatory path includes support with regulatory interactions and document authoring, along with technical, scientific and medical support and project management.
Artemida also offers flexible services covering the implementation of clinical programmes, ranging from full-service development to standalone services that are tailored to project-specific needs. The team work with their own selected team or suppliers selected by the client (guiding and representing the client where appropriate), or even with client resources, allowing them to complement their resources where necessary.
Artemida Pharma has supported companies ranging from a large multinational peri-approval programme to micro-start-ups from academia. More recently it is working with several companies in the immune-oncology field in solid tumours and photodynamic therapies as well as with targeted therapies in haematological indications.
Through its work with scientific advisory boards it has access to many key opinion leaders who help validate the development strategy. Its regulatory activities have involved successful interactions with European, US, South American and Australian regulators and ethics committees to gain IND/CTAs/ MAAs and orphan designations.